Vascular endothelial growth factor A-heparan sulfate interaction (VEGF-A-HS interaction) (VEGF-A-HS interaction)

The interaction between Vascular Endothelial Growth Factor A (VEGF-A) and Heparan Sulfate (HS) is a fundamental regulatory step in the control of angiogenesis and vascular permeability (Source: PubMed, PMID: 22431268). Heparan sulfate proteoglycans (HSPGs) located on the cell surface and in the extracellular matrix (ECM) function as co-receptors for specific VEGF-A isoforms, most notably VEGF165, which contains a dedicated heparin-binding domain (Source: UniProt, P15692). This binding sequesters VEGF-A within the ECM, creating a reservoir of the growth factor and protecting it from enzymatic degradation while simultaneously enhancing its affinity for and signaling through VEGF receptors 1 and 2 (Source: NIH, PMC2851517). In diseases such as cancer and neovascular age-related macular degeneration, this interaction is exploited to drive pathological vessel growth and leakage (Source: Nature Reviews Cancer, doi:10.1038/nrc1411). Therapeutic interventions like Aflibercept and Bevacizumab neutralize VEGF-A to prevent its interaction with both HS and its primary receptors, while heparin mimetics like Muparfostat specifically target the glycan-binding interface (Source: PubChem, CID: 11954168). Managing this interaction is clinically vital but carries risks such as hypertension and impaired wound healing due to the systemic role of VEGF in vascular health (Source: StatPearls, NBK507815).

Other names

VEGF-HSPG interactionVEGF-heparin interactionVEGF-heparan sulfate proteoglycan bindingVEGF-A-heparan sulfate interaction

Inhibition of VEGF signaling by sequestering the growth factor, preventing its association with heparan sulfate co-receptors and signaling receptors (VEGFR-1/2), or by competitively occupying the heparin-binding domain of VEGF.